Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2019 08:00 ET | Source: LogicBio Therapeutics

LogicBio Therapeutics Receives FDA Orphan Drug Designation for LB-001 for the Treatment of Methylmalonic Acidemia

CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
April 22, 2019 08:00 ET | Source: LogicBio Therapeutics

LogicBio Therapeutics Expands Leadership Team and Bolsters Capabilities to Support GeneRide™ Platform Development and Advancement of Lead Program into Clinic

CAMBRIDGE, Mass., April 22, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
April 01, 2019 08:00 ET | Source: LogicBio Therapeutics

LogicBio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat...
February 25, 2019 07:00 ET | Source: LogicBio Therapeutics

LogicBio Therapeutics to Present at Upcoming March Conferences

CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
February 22, 2019 07:00 ET | Source: LogicBio Therapeutics

LogicBio Therapeutics Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development

CAMBRIDGE, Mass., Feb. 22, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
December 06, 2018 08:00 ET | Source: LogicBio Therapeutics

LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors

CAMBRIDGE, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
December 03, 2018 08:00 ET | Source: LogicBio Therapeutics

LogicBio Reports Third Quarter 2018 Financial Results

CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat...
November 15, 2018 06:00 ET | Source: LogicBio Therapeutics

LogicBio Announces Partnership with Children’s Medical Research Institute to Develop Next Generation Viral Vectors

CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ: LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
November 13, 2018 08:00 ET | Source: LogicBio Therapeutics

LogicBio to Present at the Jefferies 2018 London Healthcare Conference

CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients...
October 23, 2018 16:05 ET | Source: LogicBio Therapeutics

LogicBio Therapeutics Announces Closing of Initial Public Offering

CAMBRIDGE, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right